# OnCo record astrum-005 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/astrum-005/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "astrum-005", "NCT04063163" ;
  schema:name "ASTRUM-005"@en ;
  schema:description "In ASTRUM-005, a Chinese PD-1 antibody produced the longest first-line survival of the chemo-immunotherapy trials; it is now approved in Europe and the UK but not yet in the US."@en ;
  schema:url <https://onco.cc/trials/astrum-005/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04063163> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-09-12" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/serplulimab/>, <https://onco.cc/drugs/platinum-etoposide/> ;
  onco:companies <https://onco.cc/companies/henlius/> ;
  onco:people <https://onco.cc/people/cheng-ying/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-astrum-005-jama-2022/> .